CVJ Stock Chart & Stats
€0.01
<€0.01(8.33%)
At close: 4:00 PM EST
€0.01
<€0.01(8.33%)
Day’s Range― - ―
52-Week Range€0.01 - €0.02
Previous CloseN/A
Volume50.00K
Average Volume (3M)2.37K
Market Cap
€3.08M
Enterprise Value€21.67
Total Cash (Recent Filing)€955.00K
Total Debt (Recent Filing)€15.10M
Price to Earnings (P/E)0.3
Beta3.84
Next Earnings
Feb 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding1,660,593,600
10 Day Avg. Volume5,100
30 Day Avg. Volume2,366
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.90
Price to Sales (P/S)0.40
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross MarginA 38.88% gross margin indicates the company achieves positive unit economics at the cultivation/processing level. Over 2-6 months this supports the possibility of returning to operating profitability if fixed overheads and sales volumes are managed, underpinning durable product-level strength.
Lean Operating BaseA small workforce (40 employees) implies a lean cost structure and operational flexibility. This lowers fixed payroll obligations, enabling the company to conserve cash, adjust capacity without large layoffs, and extend runway while pursuing contract manufacturing or selective market expansion.
Regulated Market FocusFocusing on regulated medicinal cannabis channels creates higher barriers to entry and positions the company for recurring supply contracts and contract manufacturing. Over months, regulatory-compliant supply capabilities can foster stable B2B relationships and defend market share versus informal competitors.
Bears Say
Negative Equity / Solvency RiskNegative shareholders' equity and an abnormal debt-to-equity (-27.33) are structural solvency red flags. This constrains the company’s ability to raise debt or equity on non-dilutive terms, elevates creditor risk, and may force asset sales or dilutive financing, damaging long-term strategic options.
Declining Revenue & Heavy LossesMaterial revenue decline and extreme negative margins reflect persistent operating failures. Continued structural losses erode capital, hinder investment in capacity or R&D, and make it difficult to achieve scale economies, requiring a credible multi-quarter turnaround to restore competitiveness.
Negative Cash GenerationOngoing negative operating cash flow and a 29.48% decline in free cash flow growth indicate structural cash burn. Over several months this pressures liquidity, increases reliance on external funding, raises financing costs, and risks disruption to cultivation and compliance-critical operations if not remedied.
Cann Group News
CVJ FAQ
What was Cann Group Ltd.’s price range in the past 12 months?
Cann Group Ltd. lowest stock price was €0.01 and its highest was €0.01 in the past 12 months.
What is Cann Group Ltd.’s market cap?
Cann Group Ltd.’s market cap is €3.08M.
When is Cann Group Ltd.’s upcoming earnings report date?
Cann Group Ltd.’s upcoming earnings report date is Feb 26, 2027 which is in 182 days.
How were Cann Group Ltd.’s earnings last quarter?
Currently, no data Available
Is Cann Group Ltd. overvalued?
According to Wall Street analysts Cann Group Ltd.’s price is currently Overvalued.
Does Cann Group Ltd. pay dividends?
Cann Group Ltd. does not currently pay dividends.
What is Cann Group Ltd.’s EPS estimate?
Cann Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cann Group Ltd. have?
Cann Group Ltd. has 1,660,593,600 shares outstanding.
What happened to Cann Group Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cann Group Ltd.?
Currently, no hedge funds are holding shares in DE:CVJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cann Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.60%
Trailing 12-Months
Company Description
Cann Group Ltd.
Cann Group Limited, established in Port Melbourne, Australia, in 2014, specializes in the comprehensive lifecycle of medicinal cannabis. This includes genetic development, cultivation, manufacturing, clinical assessment, and the distribution of therapeutic cannabis products. The company supplies these products for use within Australia and also exports them to international markets, operating under specific licenses that permit research and the cultivation of cannabis for human medicinal and scientific purposes.
Technical Analysis
Elixinol Wellness
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Cronos Australia Ltd.
―